Background: The effect of renal dysfunction on intracerebral hemorrhage (ICH) remains unclear. We investigated associations of renal dysfunction assessed by estimated glomerular filtration rate (eGFR) with clinical courses and outcomes in ICH patients.

Methods: From a prospective, multicenter, observational study, 203 patients who had supratentorial ICH within 3 hours of onset were included. Patients were classified into 3 groups based on eGFR: Group 1 (eGFR < 60 mL/minute/m(2)), Group 2 (60-89), and Group 3 (≥ 90). Outcomes included neurologic deterioration within 72 hours, hematoma expansion (> 33% in volume) at 24 hours, and favorable (modified Rankin Scale [mRS] ≤ 2) or unfavorable (mRS ≥ 5) outcome at 3 months.

Results: Thirty-seven patients (16 women, 74.6 ± 13.2 years) were assigned to Group 1, 99 (34 women, 65.2 ± 11.4 years) to Group 2, and 67 (30 women, 61.3 ± 9.4 years) to Group 3. Significant differences were found in age (P < .001) and initial systolic blood pressure among the groups (208.4 ± 18.0, 201.9 ± 15.1, and 198.1 ± 14.2 mm Hg for Group 1, 2, and 3, respectively; P = .006). Similar rates of neurologic deterioration (14%, 6%, and 6%) and hematoma expansion (16%, 14%, and 18%) were observed among the groups. However, in Group 1, favorable outcome was less frequent (17%, 48%, and 42%; P = .002) and unfavorable outcome was more frequent (24%, 7%, and 6%; P = .013) than in the other groups. After adjustment for confounders, eGFR < 60 mL/minute/m(2) was independently associated with both favorable outcome (odds ratio [OR], .21; 95% CI, .07-.54) and unfavorable outcome (OR, 5.64; 95% CI, 1.80-18.58).

Conclusions: Renal dysfunction (eGFR < 60 mL/minute/m(2)) was associated with poor clinical outcome after ICH.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2014.08.015DOI Listing

Publication Analysis

Top Keywords

renal dysfunction
12
egfr ml/minute/m2
12
estimated glomerular
8
glomerular filtration
8
filtration rate
8
intracerebral hemorrhage
8
group
8
neurologic deterioration
8
hematoma expansion
8
group women
8

Similar Publications

Chronic kidney disease (CKD) is often complicated by diabetes, impacting various biochemical and immunological markers. This study aimed to investigate the relationship between irisin, apelin-13, and immunological markers IL-1α and IL-1β in diabetic patients with CKD. This cross-sectional study was conducted from January to June 2023 in a tertiary care hospital in Tikrit City, Iraq.

View Article and Find Full Text PDF

Renal fibrosis (RF) is a crucial pathological factor in the progression of chronic kidney disease (CKD) to end-stage renal failure, and accurate and noninvasive assays to monitor the progression of renal fibrosis are needed. Circular RNAs (circRNAs) are noncoding RNAs that can be used as diagnostic biomarkers and therapeutic targets for human diseases. In this study, we analysed the expression of hsa_circ_0008925 in human urinary renal tubular cells and investigated its role in renal fibrosis.

View Article and Find Full Text PDF

Unraveling diabetic kidney disease: insights from single-cell RNA sequencing.

Int Urol Nephrol

January 2025

Department of Nephrology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.

The incidence of diabetic kidney disease (DKD) is rising annually. Diabetes leads to structural damage and dysfunction in the kidneys, clinically manifesting as progressive proteinuria and declining renal function, ultimately resulting in end-stage renal disease (ESRD). Recent findings have identified a subset of DKD known as normoalbuminuric diabetic kidney disease (NADKD), characterized by normal urine albumin levels but reduced renal function.

View Article and Find Full Text PDF

Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease.

Sci Rep

January 2025

Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Article Synopsis
  • SGLT2 inhibitors (SGLT2i) show promise in slowing chronic kidney disease (CKD) progression but lack extensive real-world data in diverse populations.
  • This study analyzed data from nearly 7,000 CKD patients (stages 2-4) treated with either SGLT2i or RAAS blockers to evaluate effectiveness and safety.
  • Results indicated that SGLT2i therapy was linked to a significantly lower risk of severe kidney-related events and CKD progression, with similar adverse event rates and fewer urinary tract infections compared to RAAS treatment.
View Article and Find Full Text PDF

Acute kidney injury (AKI) has been reported to occur in 30-70% of asphyxiated neonates. Hydrogen (H) gas became a major research focus in neonatal medicine after the identification of its robust antioxidative properties. However, the ability of H gas to ameliorate AKI is unknown.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!